ARTEMIS: Study of Patients With Early Stage Pancreatic Cancer Who Have Undergone Genetic Testing
Study Details
Study Description
Brief Summary
This study includes participants with pancreatic cancer who are undergoing genetic testing at Invitae related to their diagnosis of pancreatic cancer.
Our goal in this study is two-fold. First, we would like to research whether any inherited changes in genes may be associated with pancreatic cancer. Second, we would like to learn more about patient experiences with genetic testing, such as patient understanding of the testing, health-related actions taken (or planned to take) as a result of testing, communication and action of family members based on test results, and psychological impact of testing.
This research study involves allowing collection of tumor tissue (from a prior biopsy and/or surgery), a blood sample, and sending surveys to participants for their opinion on the impact of the genetic testing as well as clinicians for relevant baseline and medical history information.
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
|
Detailed Description
Patients will be contacted for patient outcomes survey completion at months: 1, 4, 8, 12, 18, 24, 30, 36, 42, 48, 54, and 60. Patients will also be contacted for survival collection every 6 months during years 3-5 post germline testing.
Clinicians will be contacted for relevant medical history, treatment, and survival data at the same time points.
At baseline, 3 samples types will be collected: 1. EDTA tube for germline genetic testing. 2. Streck tubes for whole genome sequencing and other analyses. 3. Tumor block from surgical resection. If block is unavailable 10 unstained slides are an acceptable substitute.
Study Design
Arms and Interventions
| Arm | Intervention/Treatment |
|---|---|
| Germline Pathogenic Variant in non-BRCA/PALB2 Gene Patients will receive germline testing and provide streck tube blood samples and archival tissue sample at baseline. After germline testing results have been generated and released, patients and clinicians will be contacted for survey completion at months: 1, 4, 8, 12, 18, 24, 30, 36, 42, 48, 54, 60 and survival collection every 6 months during years 3-10 post germline testing. |
Diagnostic Test: Germline genetic testing
Germline genetic testing will be provided to each patient
|
| Strong family history of pancreatic cancer but no identifiable germline pathogenic variant Patients will receive germline testing and provide streck tube blood samples and archival tissue sample at baseline. After germline testing results have been generated and released, patients and clinicians will be contacted for survey completion at months: 1, 4, 8, 12, 18, 24, 30, 36, 42, 48, 54, 60 and survival collection every 6 months during years 3-10 post germline testing. |
Diagnostic Test: Germline genetic testing
Germline genetic testing will be provided to each patient
|
| Negative germline testing and absence of strong family history Patients will receive germline testing and provide streck tube blood samples and archival tissue sample at baseline. After germline testing results have been generated and released, patients and clinicians will be contacted for survey completion at months: 1, 4, 8, 12, 18, 24, 30, 36, 42, 48, 54, 60 and survival collection every 6 months during years 3-10 post germline testing. |
Diagnostic Test: Germline genetic testing
Germline genetic testing will be provided to each patient
|
| Pathogenic Variant in BRCA1/2 or PALB2 Patients will be offered enrollment into the sister trial, APOLLO (NCT04858334). Patients and clinicians will be contacted for survey completion at months: 1, 4, 8, 12, 18, 24, 30, 36, 42, 48, 54, 60 and survival collection every 6 months during years 3-5. |
Diagnostic Test: Germline genetic testing
Germline genetic testing will be provided to each patient
|
Outcome Measures
Primary Outcome Measures
- Germline pathogenic variants identified on Invitae's 84 gene Multi Cancer panel [Will be assessed at baseline only.]
- Overall survival [Will be assessed in patient and clinician surveys distributed every 4 months for the first year post germline testing]
- Overall survival [Will be assessed every 6 months for years 2 - 10 post germline testing]
Eligibility Criteria
Criteria
Inclusion Criteria:
-
Patient has consented to germline genetic testing
-
Patient has a histologically confirmed diagnosis of pancreatic cancer
-
Patient has undergone or is planned to undergo surgical resection with curative intent
-
Patient is willing to allow collection of a tissue sample from surgical resection
-
Patient is willing to provide research blood samples (every 6 months for 2 years)
-
Patient must be at least 18 years of age
Exclusion Criteria:
-
Patient has evidence of metastatic or recurrent pancreatic cancer at time of consent
-
Patient is unable to consent.
Contacts and Locations
Locations
| Site | City | State | Country | Postal Code | |
|---|---|---|---|---|---|
| 1 | Invitae SF | San Francisco | California | United States | 94103 |
Sponsors and Collaborators
- Invitae Corporation
- Eastern Cooperative Oncology Group
Investigators
None specified.Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- CR-001-15